Hitachi and MD Anderson to investigate IMPT versus IMRT for oropharyngeal cancer

Japanese-based Hitachi's subsidiary Hitachi Healthcare Americas has signed an agreement to collaborate with the University of Texas MD Anderson Cancer Centre to evaluate the intensity-modulated proton beam therapy (IMPT) in a clinical trial for oroph …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news